Jump to content

新药进展 治疗男性勃起功能障碍1类新药昂伟达®(盐酸司美那非片)获批上市----中国科学院上海药物研究所: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

28 December 2025

  • curprev 01:1801:18, 28 December 2025 10.0.2.100 talk 1,940 bytes +1,940 Created page with "<br><br><br>值得强调的是,泰坦威的长期安全性表现优于大多数速效型产品。 一项一年期随访研究显示,超过八成用户在停用半年后仍维持明显改善,这表明它并非靠短时刺激,而是通过靶器官修复带来持久作用。 控制糖尿病HbA1c<7%、高血压血压<130/80mmHg等慢性病可改善血管性勃起障碍。<br>除了西地那非、其他磷酸二酯酶-5选择性抑制剂如伐地那非、他达..."